Inventor · disambiguated record
Liang Lu
Also filed as: LU LIANG · LU LIANG TING
36 granted patents·26 pending applications·741 citations·filing 2013–2025
98Inventor score
Files withINCYTE CORP37PRELUDE THERAPEUTICS INC11HENAN MEDINNO PHARMACEUTICAL TECH CO LTD6MEDINNO PHARMACEUTICAL TECH ZHUHAI CO LTD3DECKEN BIOTECH INC1
Top patents by PatentIndex Score
62 records- 0198US11673883B2Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2020·Granted Jun 13, 2023·12 cites·29 claims
- 0298US11530214B2Bicyclic heterocycles as FGFR inhibitorsINCYTE CORP·Filed 2021·Granted Dec 20, 2022·7 cites·26 claims
- 0398US11053246B2Substituted tricyclic compounds as FGFR inhibitorsINCYTE CORP·Filed 2020·Granted Jul 6, 2021·23 cites·10 claims
- 0498US11014923B2Bicyclic heterocycles as FGFR4 inhibitorsINCYTE CORP·Filed 2020·Granted May 25, 2021·22 cites·32 claims
- 0598US10738048B2Bicyclic heterocycles as FGFR4 inhibitorsINCYTE CORP·Filed 2019·Granted Aug 11, 2020·28 cites·21 claims
- 0698US10450313B2Bicyclic heterocycles as FGFR inhibitorsINCYTE CORP·Filed 2018·Granted Oct 22, 2019·32 cites·16 claims
- 0798US10131667B2Substituted tricyclic compounds as FGFR inhibitorsINCYTE CORP·Filed 2017·Granted Nov 20, 2018·35 cites·16 claims
- 0898US10040790B2Bicyclic heterocycles as FGFR inhibitorsINCYTE CORP·Filed 2016·Granted Aug 7, 2018·36 cites·54 claims
- 0998US9801889B2Bicyclic heterocycles as FGFR4 inhibitorsINCYTE CORP·Filed 2017·Granted Oct 31, 2017·40 cites·35 claims
- 1098US9745311B2Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitorsINCYTE CORP·Filed 2016·Granted Aug 29, 2017·45 cites·22 claims
- 1198US9611267B2Substituted tricyclic compounds as FGFR inhibitorsINCYTE CORP·Filed 2013·Granted Apr 4, 2017·54 cites·4 claims
- 1298US9580423B2Bicyclic heterocycles as FGFR4 inhibitorsINCYTE CORP·Filed 2016·Granted Feb 28, 2017·42 cites·31 claims
- 1398US9533984B2Bicyclic heterocycles as FGFR inhibitorsINCYTE CORP·Filed 2014·Granted Jan 3, 2017·42 cites·6 claims
- 1497US11840534B2Substituted tricyclic compounds as FGFR inhibitorsINCYTE CORP·Filed 2021·Granted Dec 12, 2023·4 cites·15 claims
- 1597US11667635B2Bicyclic heterocycles as FGFR4 inhibitorsINCYTE CORP·Filed 2021·Granted Jun 6, 2023·7 cites·22 claims
- 1697US10851105B2Bicyclic heterocycles as FGFR4 inhibitorsINCYTE CORP·Filed 2019·Granted Dec 1, 2020·27 cites·27 claims
- 1797US10806785B2Immunomodulator compounds and methods of useINCYTE CORP·Filed 2017·Granted Oct 20, 2020·32 cites·17 claims
- 1897US10214528B2Bicyclic heterocycles as FGFR4 inhibitorsINCYTE CORP·Filed 2018·Granted Feb 26, 2019·35 cites·20 claims
- 1997US9890156B2Bicyclic heterocycles as FGFR4 inhibitorsINCYTE CORP·Filed 2016·Granted Feb 13, 2018·40 cites·8 claims
- 2097US9708318B2Bicyclic heterocycles as FGFR4 inhibitorsINCYTE CORP·Filed 2016·Granted Jul 18, 2017·44 cites·41 claims
- 2197US9388185B2Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitorsINCYTE CORP·Filed 2013·Granted Jul 12, 2016·44 cites·21 claims
- 2295US9695168B2Substituted imidazo[1,5-α]pyridines and imidazo[1,5-α]pyrazines as LSD1 inhibitorsINCYTE CORP·Filed 2015·Granted Jul 4, 2017·27 cites·63 claims
- 2395US9695180B2Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitorsINCYTE CORP·Filed 2015·Granted Jul 4, 2017·24 cites·53 claims
- 2494US10112950B2Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitorsINCYTE CORP·Filed 2017·Granted Oct 30, 2018·15 cites·58 claims
- 2593US10640503B2Imidazopyridines and imidazopyrazines as LSD1 inhibitorsINCYTE CORP·Filed 2018·Granted May 5, 2020·7 cites·66 claims
- 2692US11702423B2BRM targeting compounds and associated methods of usePRELUDE THERAPEUTICS INC·Filed 2021·Granted Jul 18, 2023·2 cites·18 claims
- 2792US11673893B2CDK inhibitors and their use as pharmaceuticalsPRELUDE THERAPEUTICS INC·Filed 2020·Granted Jun 13, 2023·4 cites·10 claims
- 2890US10556908B2Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitorsINCYTE CORP·Filed 2018·Granted Feb 11, 2020·8 cites·37 claims
- 2979US10047086B2Imidazopyridines and imidazopyrazines as LSD1 inhibitorsINCYTE CORP·Filed 2017·Granted Aug 14, 2018·2 cites·65 claims
- 3076US2025325660A1Immunomodulator compounds and methods of useINCYTE CORP·Filed 2025·Application pending·0 cites
- 3174US11629148B2Substituted pyrrolo[3,4-d]imidazoles as JAK inhibitorsHENAN MEDINNO PHARMACEUTICAL TECH CO LTD·Filed 2021·Granted Apr 18, 2023·1 cites·16 claims
- 3272US2024018158A1Brm targeting compounds and associated methods of usePRELUDE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3371US12486277B2CDK inhibitors and their use as pharmaceuticalsPRELUDE THERAPEUTICS INC·Filed 2023·Granted Dec 2, 2025·0 cites·23 claims
- 3470US2023226062A1Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2022·Application pending·0 cites
- 3568US2019127376A1Substituted tricyclic compounds as fgfr inhibitorsINCYTE CORP·Filed 2018·Application pending·0 cites
- 3664US2020397893A1Immunomodulator compounds and methods of useINCYTE CORP·Filed 2020·Application pending·0 cites
- 3762US2020181126A1Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2020·Application pending·0 cites
- 3861US2025011298A1Crystalline forms of a cdk9 inhibitor and uses thereofPRELUDE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3961US2024336612A1BRM Targeting Compounds And Associated Methods Of UsePRELUDE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4059US2024190886A1BRM Targeting Compounds and Associated Methods of UsePRELUDE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 4159US2025017207A1Fungicidal compositionsSYNGENTA CROP PROTECTION AG·Filed 2022·Application pending·0 cites
- 4258US12180215B2Substituted pyrrolo[3,4-d]imidazoles as JAK inhibitorsHENAN MEDINNO PHARMACEUTICAL TECH CO LTD·Filed 2023·Granted Dec 31, 2024·0 cites·19 claims
- 4358US12122855B2Method for extracting pullulan polysaccharide from high-viscosity fermentation brothTIANJIN UNIV OF SCIENCE AND TECHNOLOGY·Filed 2024·Granted Oct 22, 2024·0 cites·11 claims
- 4457US2023144528A1CDK Inhibitors And Their Use As PharmaceuticalsPRELUDE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4557US2023365576A1BRM Targeting Compounds And Associated Methods Of UsePRELUDE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 4657US2018177784A1Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2017·Application pending·0 cites
- 4754US10016438B2Bicyclic heterocycles as FGFR4 inhibitorsINCYTE CORP·Filed 2017·Granted Jul 10, 2018·0 cites·31 claims
- 4854US2022388992A1Jak inhibitor compound and use thereofLU LIANG·Filed 2022·Application pending·0 cites
- 4954US2017320877A1Bicyclic heterocycles as fgfr4 inhibitorsINCYTE CORP·Filed 2017·Application pending·0 cites
- 5053US2017342060A1Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2017·Application pending·0 cites
Showing the top 50 of 62 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Liang Lu files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →